---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-26-000044"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2026-08-03T20:06:40+00:00"
generated_at: "2026-08-03T20:08:48.385317+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma Q2 2026: record revenue $1.2B (+16% YoY); raises FY2026 guidance to $4.60-$4.75B

## Summary
- Total revenues of $1.2B, a record, up 16% YoY; GAAP EPS $2.78, non-GAAP adjusted EPS $5.71.
- Xywav revenues +13% YoY with 525 net patient adds in Q2; Epidiolex revenues +16% YoY.
- Company raises 2026 revenue guidance to $4.60-$4.75B, reflecting double-digit growth from Xywav and epilepsy/oncology.
- FDA set PDUFA date of Aug 25, 2026 for zanidatamab sBLA in 1L GEA; BTD granted for HER2+ CRC.
- Cash from operations $824M in first half 2026; strong balance sheet supports pipeline and launches.

## SEC filing metadata
- accession: 0001232524-26-000044
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2026-08-03T20:06:40+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/0001232524-26-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/jazz-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-26-000044
- JSON: https://secwatch.observer/filing/0001232524-26-000044.json
- Plain text: https://secwatch.observer/filing/0001232524-26-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.